Form 4: Corcept Therapeutics Officer Lyon Reports Stock Transaction

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, reports the acquisition and disposal of company stock on April 1, 2024, pursuant to a 10b5-1 plan.

Summary

• On April 1, 2024, Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, engaged in a transaction involving Corcept Therapeutics [CORT] common stock.
• Lyon acquired 500 shares of common stock at a price of $11.35 per share through the exercise of a stock option.
• Concurrently, Lyon disposed of 500 shares of common stock at a price of $26.007 per share.
• The transaction was executed under a pre-existing 10b5-1 plan.
• Following the reported transactions, Lyon beneficially owns 7,314 shares of Corcept Therapeutics common stock.
• This total includes 1,411 shares underlying unvested restricted stock awards granted on June 1, 2023, 361 shares underlying unvested restricted stock awards granted on September 1, 2023, 460 shares underlying unvested restricted stock awards granted on December 1, 2023, and 507 shares underlying unvested restricted stock awards granted on March 1, 2024.
• 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
• Lyon also holds options to purchase 42,667 shares of common stock at an exercise price of $11.35, which are fully exercisable.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing, and the transactions appear to be part of a pre-planned strategy. Therefore, the sentiment is neutral.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. The use of a 10b5-1 plan suggests that the transactions were pre-planned and not based on any material non-public information.

Comparison to Industry Standards

• Insider trading activity is common across publicly listed companies, and the reported transactions are typical for executives exercising stock options and selling shares.
• The use of a 10b5-1 trading plan is a standard practice to avoid accusations of illegal insider trading, similar to practices employed by executives at companies like Pfizer or Amgen.
• The vesting schedules for restricted stock awards are also typical, often tied to continued employment and performance metrics, which aligns with industry standards at companies like Biogen or Gilead Sciences.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan suggests that the transactions were pre-planned and not based on any material non-public information.
• The vesting of restricted stock awards incentivizes the Reporting Person to remain with the company and contribute to its success, which benefits employees and shareholders.

Key Dates